PATENT CLAIM ANALYSIS

Application Number: 16297904
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "211090"]

Abstract:
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Claim (Index 30):
The method of  claim 1 , wherein the compound or the pharmaceutically acceptable salt is administered to the patient, and the compound is

Metadata:
- Claim Count in Document: 63.0
- Percentile: 99.0
- Lexical Diversity: 1.57692
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15938001', '15376456', '14839149', '16123030', '13546713']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7741420516641057
- 35 USC 102 Novelty (BERT): 0.684972652614108
- Combined Prediction Score: 0.7652251117591059
- Mean Citation Score: 449.2510899999999
- Max Citation Score: 798.7884
- Similarity Product: 645.0747712416173

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test